DAPK1 and adenomyoma: Regarding the source of control samples, 10 studies evaluated DAPK1 promoter methylation in BCT from patients having gynaecological diseases such as uterine myoma, adenomyoma, and uterine prolapse, 8 studies in NT from healthy people and 2 studies in normal cervical tissues adjacent to the tumor.